✦ LIBER ✦

9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma

✍ Scribed by Vanazzi, A.; Pruneri, G.; Crosta, C.; Grana, C.; Rizzo, S.; Radice, D.; Steffanoni, S.; Pinto, A.; Paganelli, G.; Martinelli, G.

Book ID: 123553577
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71898-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of yttrium-90 ibritu

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma

✍ Makoto Nakagawa, Naokuni Uike, Ilseung Choi… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 211 KB

Recommendations for the use of Yttrium-9

Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

✍ Oliver Weigert; Tim Illidge; Wolfgang Hiddemann; Martin Dreyling 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB

Safety and Efficacy of Yttrium-90 Ibritu

Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma

✍ Emmanouilides, Christos; Witzig, Thomas E.; Wiseman, Gregory A.; Gordon, Leo I.; 📂 Article 📅 2007 🏛 Mary Ann Liebert 🌐 English ⚖ 149 KB

Radioimmunotherapy in Non-Hodgkin's Lymp

Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90–Labeled Ibritumomab Tiuxetan and Beyond

✍ Evens, Andrew M.; Gordon, Leo I. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 129 KB

Radioisotopic Localization of90Yttrium–I

Radioisotopic Localization of90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma

✍ S. A. Jacobs; A. M. Harrison; S. H. Swerdlow; K. A. Foon; N. Avril; N. Vidnovic; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 589 KB

P166 Experience with the use of yttrium-

P166 Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

✍ J. Demeter; K. Balassa; M. D¨om¨ot¨or; M. Egyed; Z. Gasztonyi; H. Aryab; M. Gurz 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

cursor was set to the same position in each sample, where 5% of T/NK cells were Zap-70 negative. Zap-70 and CD38 labeling was determined on CD19+ cells. Results: With dichotomized evaluation of CD38 and Zap-70 expression 70% of the cases showed concordant results: 32% were Zap-70+/CD38+ and 38% were